Cholestasis Pruritus Treatment Market Report 2025 (Global Edition)

Global Cholestasis Pruritus Treatment Market Report 2025 Market Size Split by Type (Corticosteroids, Antihistamines), by End Use (Clinic, Hospital), by Disease Type (Skin, Atopic Dermatitis, Allergic,...

Cholestasis Pruritus Treatment Market Report Description

We have various report editions of Cholestasis Pruritus Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Cholestasis Pruritus Treatment Market Insights Video

Competitive Landscape of Cholestasis Pruritus Treatment Market

The growing interest in cholestasis pruritus treatment has attracted startups and emerging players. These companies often bring fresh perspectives and innovative ideas to the table. They may focus on repurposing existing drugs for cholestasis pruritus treatment or developing new compounds.

• September 2022: Cara Therapeutics Inc. announced findings from the KOMFORT Phase 2 clinical trial involving oral difelikefalin's use in treating moderate-to-severe pruritus in notalgia paresthetica (NP). The results were showcased at the 31st European Academy of Dermatology and Venereology (EADV) Congress, featuring data collected from 125 NP patients.

(Source: ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-results-komfort-phase-2-trial-oral)

• August 2022: The European Commission has granted marketing authorization to Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics Inc. for Kapruvia (difelikefalin), designed to address moderate-to-severe pruritus linked to chronic kidney disease (CKD) among adult hemodialysis patients.

(Source: www.biopharminternational.com/view/kapruvia-approved-by-ec-for-treatment-of-pruritus#:~:text=Vifor%20Fresenius%20Medical%20Care%20Renal,disease%20(CKD)%20in%20adult%20hemodialysis)

• June 2020: Cara Therapeutics, a clinical-stage biopharmaceutical firm, reported the successful conclusion of its Phase-ll dose-ranging study involving oral Korsuva for addressing moderate to severe pruritus linked to chronic kidney disease. This achievement is anticipated to enhance competitiveness within the projected timeframe.

(Source: ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-results-komfort-phase-2-trial-oral)

Top Companies Market Share in Cholestasis Pruritus Treatment Industry: (In no particular order of Rank)

• Intercept Pharmaceuticals
• Albireo Pharma
• Shionogi & Co.
• Dr. Falk Pharma
• GlaxoSmithKline
• Zydus Cadila
• Mylan N.V.
• CymaBay Therapeutics
• Genfit
• Takeda Pharmaceutical Company
• Novartis
• Daewoong Pharmaceutical
• Teva Pharmaceuticals
• AbbVie Inc.
• Pfizer Inc.
• Alfa Wassermann
• Recordati Rare Diseases
• Kyowa Kirin
• Sawai Pharmaceutical Co.
• Sun Pharmaceutical Industries
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

North American Cholestasis Pruritus Treatment dominates the market in 2022

According to Cognitive Market Research, North America dominated the market in 2022 and accounted for a share of more than 35% of the global revenue due to several variables. Due to several key factors, North America has secured the largest market share in cholestasis pruritus treatment. The region benefits from advanced healthcare infrastructure, enabling early diagnosis and comprehensive management. Robust research and innovation capabilities drive the development of effective treatments. The presence of major pharmaceutical companies facilitates drug development and clinical trials. High healthcare expenditure supports R&D initiatives and treatment accessibility. Skilled medical professionals ensure accurate diagnosis and patient care. Extensive awareness campaigns and patient education efforts promote understanding and early intervention. Favorable regulatory frameworks streamline drug approval processes.

Furthermore, collaborations between research institutions, medical communities, and industry players accelerate innovation. These factors collectively establish North America as a frontrunner in cholestasis pruritus treatment, driving its market growth and prominence.

Europe's rapid growth in cholestasis pruritus treatment can be attributed to its well-established healthcare infrastructure, strong emphasis on medical research, and increasing awareness about this condition. The region's collaborative approach between healthcare providers and pharmaceutical companies fosters the development and adoption of innovative treatment solutions. Moreover, regulatory frameworks promote efficient drug approval processes. These factors and a growing patient population seeking advanced therapies position Europe as the fastest-growing region in cholestasis pruritus treatment.

The current report Scope analyzes Cholestasis Pruritus Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

Cholestasis Pruritus Treatment Market Analysis

Type Segment Analysis

Corticosteroids have gained the largest market share in cholestasis pruritus treatment due to their potent anti-inflammatory and immunosuppressive properties. They effectively alleviate itching and inflammation associated with cholestasis. Their wide availability, versatility in formulations, and proven efficacy make them popular among healthcare providers. Additionally, corticosteroids are often considered for short-term relief in acute cases. While potential side effects and long-term use limitations exist, proper medical supervision mitigates these concerns. Overall, the combination of effectiveness, familiarity, and accessibility has contributed to corticosteroids' dominance in the cholestasis pruritus treatment market.

Antihistamines have secured the second-largest market share in cholestasis pruritus treatment due to their ability to block histamine receptors, reducing itching and discomfort. They are readily available over-the-counter and in prescription forms, making them accessible for patients seeking relief. Antihistamines' established safety profile and relatively mild side effects contribute to their popularity. While not always as potent as other options, their ease of use, broad patient applicability, and tolerability have positioned antihistamines prominently in the cholestasis pruritus treatment landscape.

• Corticosteroids
• Antihistamines

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Cholestasis Pruritus Treatment Industry. Request a Free Sample PDF!

End-Use Segment Analysis

Hospitals have claimed the largest market share in cholestasis pruritus treatment due to their comprehensive medical resources and specialized expertise. Cholestasis-related pruritus often requires multidisciplinary care involving hepatologists, dermatologists, and other specialists. Hospitals provide an environment for collaborative diagnosis and treatment planning, incorporating advanced diagnostics and therapies. Inpatient settings allow for close monitoring and immediate intervention for severe cases. 

Clinics have secured the second-largest market share in cholestasis pruritus treatment due to their specialized care delivery. These settings offer a balance between comprehensive care and outpatient convenience. Clinics often house dermatologists, hepatologists, and other relevant specialists, allowing for tailored treatment plans. Their accessibility and focus on specific medical conditions make them the preferred options for routine care and management of cholestasis pruritus.

• Clinic
• Hospital

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Cholestasis Pruritus Treatment Disease Type Segment Analysis

Skin disease type, including cholestasis-related pruritus, has acquired the largest market share in cholestasis pruritus treatment due to its direct connection to patient symptoms. Tailoring treatments to specific skin disease types allows for targeted interventions, optimizing therapeutic outcomes. More effective and specialized treatment options are emerging as research delves deeper into understanding the underlying mechanisms of different skin diseases. The focus on treating the root cause of pruritus linked to cholestasis ensures better patient outcomes, driving the prominence and growth of this treatment approach in the market.

With its prevalence and impact on pruritus, atopic dermatitis has secured the second-largest market share in cholestasis pruritus treatment. Shared pathways between atopic dermatitis and cholestasis-related itching enable the adaptation of therapies. The demand for effective treatments for atopic dermatitis-associated pruritus has driven research and innovation, resulting in specialized options. Its recognition as a significant contributor to cholestasis pruritus and targeted treatment advancements has propelled atopic dermatitis to a substantial position in the treatment landscape.

• Skin
• Atopic Dermatitis
• Allergic
• Internal Diseases

Cholestasis Pruritus Treatment Treatment Type Segment Analysis

Creams and ointments have dominated the cholestasis pruritus treatment market, offering localized, direct application to affected skin areas. Their convenience, ease of use, and ability to provide targeted relief make them the preferred choices for managing itching and discomfort. Additionally, these topical formulations allow different active ingredients to be incorporated, catering to varying patient needs. 

Oral treatments, securing the second largest market share in cholestasis pruritus treatment, offer systemic relief for widespread symptoms. These treatments address itching from within, making them suitable for cases with insufficient localized options. Their ability to target underlying causes and provide holistic relief has garnered attention.

• Creams and Ointments
• Oral

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion